 |
| MMWR Weekly Vol. 65, No. 18 May 13, 2016 |
| PDF of this issue |
Identification and Clinical Management of Persons with Chronic Hepatitis C Virus Infection — Cherokee Nation, 2012–2015
Weekly / May 13, 2016 / 65(18);461–466
Jorge Mera, MD1; Claudia Vellozzi, MD2; Susan Hariri, PhD2; Hélène Carabin, DVM, PhD3; Douglas A. Drevets, MD3,4; Anna Miller, MD1; Brigg Reilley, MPH5; Whitney Essex, APRN1; David Gahn, MD1; Lisa Lyons, MSc1; Jessica Leston, MPH6; John W. Ward, MD2 (View author affiliations)
View suggested citationSummary
What is already known about this topic?Hepatitis C virus (HCV) infection, the most common bloodborne infection in the United States, is the leading cause of liver-related mortality and disproportionally affects the American Indian/Alaska Native (AI/AN) populations. New all-oral HCV therapies can halt disease progression and provide a cure, but increased testing is needed to identify persons living with chronic HCV infection because more than half of infected persons are unaware of their infection.
What is added by this report?Beginning in October 2012, Cherokee Nation Health Services (CNHS) implemented measures to improve HCV testing and care among the AI/AN population in northeastern Oklahoma. During October 2012–July 2015, the percentage of all persons tested for the first time increased fivefold. HCV treatment was initiated for more than half of the approximately 400 patients identified with chronic HCV infection, 90% of whom completed treatment and were cured.
What are the implications for public health practice?CNHS successfully increased HCV testing and treatment and is now collaborating with external partners to develop an HCV elimination program for the Cherokee Nation that might serve as a model for similar settings.
An estimated 3.5 million persons in the United States are living with hepatitis C virus (HCV) infection, resulting in approximately 20,000 deaths each year, primarily from cirrhosis or hepatocellular carcinoma (1,2). American Indian/Alaska Native (AI/AN) populations have the highest incidence of acute HCV infection among all U.S. racial/ethnic groups and are at greater risk for HCV-related mortality compared with the general population (3). In 2013, new antiviral drugs became available that make possible 8–12 week treatment regimens with fewer adverse events and are able to achieve sustained virologic response (SVR) in >90% of treated patients (4), equivalent to a cure of HCV infection. Also of note, HCV testing recommendations were expanded in 2012 by CDC and in 2013 by the U.S. Preventive Services Task Force to include one-time testing of persons born during 1945–1965 (the “baby boomer” cohort) in addition to anyone at increased risk for HCV infection (5,6). Given the availability of new HCV drugs, expanded testing recommendations, and high incidence of HCV infection in AI/AN populations, in October 2012, Cherokee Nation Health Services (CNHS) implemented a tribal HCV testing policy.* As part of the policy, CNHS added a reminder in the electronic health record (EHR) for clinical decision support and provided HCV education to primary care clinicians. From October 2012 to July 2015, among 92,012 persons with at least one CNHS clinic encounter, the cumulative number who received HCV screening for the first time increased from 3,337 (3.6%) to 16,772 (18.2%). The largest percentage of HCV screening was among persons born during 1945–1965. Of 715 persons who tested positive for HCV antibodies, 488 (68.3%) were tested for HCV RNA; among those 488 persons, 388 (79.5%) were RNA positive and were thus confirmed to have chronic HCV infection. Treatment was initiated for 223 (57.5%) of the 388 with chronic infection; 201 (90.1%) completed treatment, of whom 180 (89.6%) achieved SVR. CNHS has successfully increased HCV testing and treatment and is now collaborating with CDC and other external partners to develop an HCV elimination program for the Cherokee Nation that might serve as a model for similar settings.
The Cherokee Nation is a federally recognized government of more than 317,000 sovereign Cherokee persons in the United States. CNHS is an independent network that includes one hospital and eight clinics with a centralized EHR system providing care to approximately 131,000 AI/ANs (87% Cherokee and 13% other federally recognized tribes) in 14 counties of primarily rural northeastern Oklahoma.
During October 2012–2015, an infectious diseases specialist serving CNHS provided in-person hepatitis C training to clinicians and allied health professionals in each health care facility. Fifteen workshops were organized with a total of 291 participants. In response to the expanded national HCV testing recommendations, CNHS collaborated with the Indian Health Service (IHS) to design and implement an EHR reminder to test patients born during 1945–1965. Beginning in August 2013, the EHR reminder was added on a rolling basis depending on local priorities and capacity, reaching all primary care clinics by January 2014. The EHR prompt targeted any person born during 1945–1965 who had at least one medical visit in the preceding 3 years and no documented HCV antibody test in the medical record.
In conjunction with expanded testing, CNHS increased capacity to provide care for HCV-infected patients as well as to decrease patients’ waiting and travel time for evaluation. The Extension for Community Healthcare Outcomes (ECHO) telehealth program (7,8) was implemented in July 2014 to increase primary care provider capacity to care for HCV-infected patients. ECHO implementation enabled expansion of HCV care and treatment services from one clinic with one health care provider with expertise in HCV care to five clinics staffed by seven HCV-trained health care providers, including three physicians, two nurse practitioners, and two pharmacists. In January 2014, an HCV registry was established to monitor clinical care for HCV RNA-positive patients who initiated antiviral treatment. The registry is maintained by the infectious diseases clinic of CNHS. In October 2015, public health nurses began outreach activities for HCV-infected patients, including home visits.
To evaluate the impact of the new testing and care and treatment strategies, de-identified data from the CNHS centralized EHR system and the HCV registry were extracted and analyzed. HCV testing coverage was calculated as the proportion of patients with at least one clinical encounter with CNHS during October 2012–July 2015 who received one or more HCV antibody tests during that period. Progression along the steps of the cascade of care was examined by two methods: 1) the percentage of persons with HCV antibodies who completed each step, and 2) the percentage of persons at each step who moved to the next step. SVR was defined as undetectable HCV RNA obtained at least 12 weeks after the end of treatment. Advanced liver disease was determined based on noninvasive liver staging methods as identified by serologic biomarkers (fibrosis-4 index >3.25) (9).
During October 2012–July 2015, a total of 92,012 patients aged ≥20 years had at least one medical encounter with CNHS. Among these patients, 90% were residents of the 14-county CNHS tribal jurisdictional area, 56% were female, and 29.4% were born during 1945–1965. The cumulative proportion of the population tested for HCV antibodies increased fivefold, from 3.6% to 18.2%, and did not differ by sex. By July 2015, the largest cumulative percentage of persons tested (39.5%) were in the baby boomer cohort (1945–1954 and 1955–1964), representing a sixfold increase (Figure 1).
Among the 16,772 patients tested for HCV antibody, 715 (4.3%) were antibody-positive. Among the HCV antibody-positive patients, 488 (68.3%) had a confirmatory HCV RNA test performed, of whom 388 (79.5%) were found to be chronically infected (HCV RNA-positive). More than half (57.5%) of persons with chronic HCV infection initiated treatment, of whom 89.6% achieved SVR (Figure 2).
Among the 223 patients initiating treatment, HCV genotype 1 (GT1) was the most common infection (157 patients, 70.4%), followed by GT2 (35 patients, 15.7%), GT3 (30 patients, 13.5%) and GT4 (one patient, 0.5%). Among the 134 patients in the baby boomer birth cohort, 50 (37.3%) were found to have advanced liver disease. Among the 86 patients with chronic HCV infection born after 1965, 23 (26.7%) had evidence of advanced liver disease. Seven patients who initiated treatment failed to complete treatment because of noncompliance (four), psychiatric complications (two), and pregnancy (one). Twenty-one patients were lost to follow up (including one who died) before testing for SVR.
As direct, oral, interferon-free antiviral agents became available and clinic capacity improved, the number of patients treated for chronic HCV infection increased over time. More than 15 patients (range = 16–31) initiated treatment in eight of the 19 months (Figure 3).
Discussion
HCV antibody testing by CNHS increased fivefold over the approximately 33-month evaluation period. As of July 2015, testing coverage among persons in the baby boomer birth cohort was nearly 40%. The substantial increase in the number of tests ordered among persons born during 1945–1965 likely resulted from implementation of the EHR reminder in August 2013. Although the EHR reminder specifically targeted the baby boomer birth cohort, HCV testing also increased among other birth cohorts during this period, although to a lesser degree. Increased testing in younger populations could have resulted from enhanced primary care provider education and more awareness of HCV-related risk factors. Over the entire 33-month period, only 57.5% of eligible patients initiated treatment; however, the number of patients initiating treatment increased substantially over time. The increase occurred during a period when interferon-free oral, anti-HCV agents became available and followed implementation of the ECHO program and enhanced primary care education and training in July 2014.
The increase in HCV testing and case finding increased the need for HCV RNA confirmatory testing and linkage to care. Approximately 30% of patients found to be HCV antibody–positive had not received a confirmatory HCV RNA test. Furthermore, among patients identified with chronic HCV infection, 32% had advanced liver disease and needed immediate treatment. There is a clear need for increased health care capacity to identify and treat persons with chronic HCV infection to prevent further morbidity and mortality. Thus, the role of primary care providers has been critical in addressing the clinical needs of the growing volume of patients identified with HCV infection. Another important component of increasing capacity has been the work of public health nurses in outreach activities for patients infected with HCV, including making home visits and drawing blood for further testing (i.e., for HCV RNA), if needed. CNHS has posted fliers in clinic waiting areas to prompt patients who might already know they are HCV antibody–positive to contact one of the clinics that provides HCV care. The Cherokee Nation is systematically continuing to identify and treat chronic HCV infection, and expanding clinical capacity to meet patient needs by leveraging telehealth within its primary care delivery system. The Cherokee Nation has declared October 30 as CNHS HCV Awareness Day.
The findings in this report are subject to at least four limitations. First, the results are not generalizable to other populations because they were specific to the AI/AN community managed in a specific tribal health care system. Second, the data were observational, and the outcomes cannot be directly attributed to the interventions. Third, the availability of three new oral antiviral regimens during this period (sofosbuvir in January 2014, sofosbuvir/ledipasvir in October 2014, and ombitasvir/paritaprevir/ritonavir/dasabuvir in December 2014) might have contributed to the observed increase in antiviral treatments in addition to the reported increase in clinical capacity. Finally, the cascade of care does not include a population-based estimate of the number of HCV cases because these data are not yet available.
In response to findings of the expanded CNHS testing initiative, in October 2015, with the assistance of CDC and other partners, the Cherokee Nation launched The Path Toward Elimination of HCV program. The Cherokee Nation is committed to implementing a comprehensive program with goals for eliminating HCV as a health disparity for the population. The program includes expansion of a clinical phase to implement broad-based HCV testing, care, and treatment activities in CNHS with the goal of treating 85% of CNHS patients with HCV infection over a 3-year period. As a first step, tribal HCV screening policy was expanded to include persons aged 20–69 years. In addition, CNHS is striving to increase clinical capacity to 20 providers and eight pharmacists trained as HCV care providers. A second phase will be a community-based effort to implement interventions as necessary to interrupt HCV transmission, focused primarily on persons who inject drugs.
Currently CNHS is collaborating with the Cherokee Nation Tribal Council, Cherokee Nation Public Health, CDC, the University of Oklahoma Health Sciences Center, Yale School of Public Health, Oklahoma State Department of Health, Gilead Foundation, and community-based organizations to develop effective strategies and programs to prevent, test, treat, and cure HCV infection. Cherokee Nation’s HCV elimination program is the first of its kind in the United States. The National Academies of Science, Engineering, and Medicine currently is examining the feasibility of eliminating hepatitis C in the United States and developing recommendations for specific actions to hasten the end of HCV transmission and disease (10).
Acknowledgments
Tara Ritter, DNP; Jennifer Shade, MBA; Kristin Meyers; Amanda Hicks; Rachel Ray, MD; Adam Sprankle, MD; Karie Benham; Julie Gaskins, ARNP; Cheryl Mike; Dwayne David, PharmD; Weston Lovell, PharmD; Crystal David, PharmD; Kendra Round, APRN; Evon Ashley; Patricia Hawk; Roger Montgomery, MD; Brian Hail, MBA; Connie Davis, MSN; Douglas Nolan, DO, Charles Grim, DDS; Lisa Neel, MPH; Karla Thornton, MD; James Stallcup, MD; Lisa Pivec, MS; Mary Williams, PhD; Sohail Kahn, MBBS, MPH.
Corresponding author: Jorge Mera, Jorge-Mera@cherokee.org, 918-458-3360.
1Cherokee Nation Health Services; 2Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC; 3University of Oklahoma Health Sciences Center; 4Oklahoma City Veterans Affairs Medical Center; 5Indian Health Service; 6Northwest Portland Area Indian Health Board.
References
- Edlin BR, Eckhardt BJ, Shu MA, Holmberg SD, Swan T. Toward a more accurate estimate of the prevalence of hepatitis C in the United States. Hepatology 2015;62:1353–63. CrossRefPubMed
- Ly KN, Xing J, Klevens RM, Jiles RB, Holmberg SD. Causes of death and characteristics of decedents with viral hepatitis, United States, 2010. Clin Infect Dis 2014;58:40–9. CrossRefPubMed
- CDC. Viral hepatitis surveillance, United States; 2013. Atlanta, GA: US Department of Health and Human Services, CDC; 2014.http://www.cdc.gov/hepatitis/statistics/2013surveillance/pdfs/2013hepsurveillancerpt.pdf
- Bansal S, Singal AK, McGuire BM, Anand BS. Impact of all oral anti-hepatitis C virus therapy: a meta-analysis. World J Hepatol 2015;7:806–13. CrossRef PubMed
- Smith BD, Morgan RL, Beckett GA, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. MMWR Recomm Rep 2012;61(No. RR-4). PubMed
- US Preventive Services Task Force. Final recommendation statement, hepatitis C: screening; 2013. Rockville, MD: US Preventive Services Task Force; 2013.http://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/hepatitis-c-screening
- Arora S, Thornton K, Murata G, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med 2011;364:2199–207. CrossRef PubMed
- Mitruka K, Thornton K, Cusick S, et al. Expanding primary care capacity to treat hepatitis C virus infection through an evidence-based care model—Arizona and Utah, 2012–2014. MMWR Morb Mortal Wkly Rep 2014;63:393–8. PubMed
- Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology 2007;46:32–6.CrossRef PubMed
- National Academies of Sciences, Engineering, and Medicine. 2016. Eliminating the public health problem of hepatitis B and C in the United States: phase one report. Washington, DC: The National Academies Press. http://www.nap.edu/read/23407/chapter/1
* A Cherokee translation of this report will be available in June in the hepatitis C awareness section at http://cherokeepublichealth.org/. The title of this report translates as follows: ᎪᏟᏍᏙᏗ ᎠᎴ ᎠᎦᏛᏂᏓᏍᏗ ᎥᏳᎩ ᎤᏁᎲᎢ ᏴᏫ ᎪᎯᎩ ᏄᏁᎰᎢ ᎤᏪᎶᎢ ᎥᏳᎩ (HCV) ᏚᎾᏓᏂᎶᎯᏍᏗᎲᎢ ᎥᎿᎾᏂ ᏣᎳᎩᎯ ᎠᏰᎵ, 2012–2015.
FIGURE 1. Cumulative percentage of persons who received one or more hepatitis C virus antibody tests, by birth cohort — Cherokee Nation Health Services, October 2012–July 2015
FIGURE 2. Percentages for 715 hepatitis C virus (HCV) antibody-positive patients, showing cascade of care — Cherokee Nation Health Services, October 2012–July 2015
Abbreviation: SVR = sustained virologic response.
.png)
No hay comentarios:
Publicar un comentario